Pemigatinib for patients with previously treated, locally advanced or metastatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements: a joint analysis of the multicenter, observational, real-world French PEMI-BIL and Italian PEMI-REAL cohort studies
Alessandro Parisi,Blandine Delaunay,Giada Pinterpe,Antoine Hollebecque,Jean Frederic Blanc,Mohamed Bouattour,Eric Assenat,Meher Ben Abdelghani,Matthieu Sarabi,Monica Niger,Caterina Vivaldi,Mario Mandalà,Andrea Palloni,Maria Bensi,Silvio Ken Garattini,David Tougeron,Pierre Combe,Massimiliano Salati,Margherita Rimini,Chiara Alessandra Cella,Marco Tucci,Anna Diana,Elena Mori,Raffaella Longarini,Pascal Artru,Gael Roth,Ludovic Evesque,Agathe Vienne,Anthony Turpin,Sandrine Hiret,Vincent Bourgeois,Camille Herve,Rodolphe Paulon,Marion Stacoffe,David Malka,Cindy Neuzillet,Julien Edeline,Astrid Lievre,Rosine Guimbaud,Marie Christelle Pajiep Tchapda,Lorenza Rimassa,Riccardo Giampieri,Juan Valle,Rossana Berardi,Nadim Fares
DOI: https://doi.org/10.1016/j.ejca.2024.113587
IF: 10.002
2024-02-07
European Journal of Cancer
Abstract:Background Pemigatinib is approved for patients with pretreated, locally advanced or metastatic CCA harboring FGFR2 rearrangements or fusions. We aim to assess the effectiveness and safety of pemigatinib in real-world setting. Material and Methods A joint analysis of two multicentre observational retrospective cohort studies independently conducted in France and Italy was performed. All consecutive FGFR2-positive patients affected by CCA and treated with pemigatinib as second- or further line of systemic treatment in clinical practice, within or outside the European Expanded Access Program, were included. Results Between July 2020 and September 2022, 72 patients were treated with pemigatinib in 14 Italian and 25 French Centres. Patients had a median age of 57 years, 76% were female, 81% had ECOG-PS 0-1, 99% had intrahepatic CCA, 74% had ≥ 2 metastatic sites, 67% had metastatic disease at diagnosis, while 38.8% received ≥ 2 previous lines of systemic treatment. At data cut-off analysis (April 2023), ORR and DCR were 45.8% and 84.7%, respectively. Median DoR was 7 months (IQR: 5.8-9.3). Over a median follow-up time of 19.5 months, median PFS and 1-year PFS rate were 8.7 months and 32.8%. Median OS and 1-year OS rate were 17.1 months and 60.6%. Fatigue (69.4%), ocular toxicity (68%), nail toxicities (61.1%), dermatologic toxicity (41.6%) hyperphosphataemia (55.6%), stomatitis (48.6%), and diarrhea (36.1%) were the most frequent, mainly G1-G2 AEs. Overall incidence of G3 AEs was 22.2%, while no patient experienced G4 AE. Dose reduction and temporary discontinuation were needed in 33.3% and 40.3% of cases, with 1 permanent discontinuation due to AEs. Conclusions These results confirm the effectiveness and safety of pemigatinib in a real-world setting.
oncology